Physician profile
Warren Pitts
NPI 1033253265
$7,609.76
in general payments reported to CMS, 2019-2025
35 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $852 · 2020: $902 · 2021: $1,089 · 2022: $1,125 · 2023: $1,200 · 2024: $1,273 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606 · Education: $35.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.13 |
| Education | $35.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,674.48 | 2019-2025 | |
| Boston Scientific Corporation | $1,016.51 | 2019-2024 | Exalt Model D, Axios, Spyglass |
| Fujifilm Healthcare Americas Corporation | $631.11 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $512.17 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $487.25 | 2019-2025 | |
| Janssen Biotech, INC. | $354.66 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $287.12 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $241.38 | 2019-2025 | Entyvio, Gattex |
| Qol Medical, LLC | $181.23 | 2019-2025 | Sucraid, Sucraid |
| Olympus America INC. | $150.00 | 2020 | |
| Merck Sharp & Dohme LLC | $146.32 | 2019-2024 | Dificid |
| Smith+Nephew, INC. | $144.07 | 2023 | Oasis |
| Intuitive Surgical, INC. | $128.67 | 2022 | |
| Allergan, INC. | $128.23 | 2019 | |
| Nestle Healthcare Nutrition INC. | $126.62 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $125.96 | 2022-2025 | |
| Gilead Sciences, INC. | $123.90 | 2019-2025 | |
| Ucb, INC. | $117.54 | 2019 | |
| Celgene Corporation | $114.95 | 2022-2024 | Zeposia |
| Echosens North America, INC. | $106.67 | 2025 | Fibroscan |
| Madrigal Pharmaceuticals | $91.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $84.77 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $84.68 | 2022-2025 | Dupixent |
| Axonics, INC. | $82.51 | 2024 | Axonics |
| Ferring Pharmaceuticals INC. | $78.26 | 2020-2022 | |
| Medtronic, INC. | $68.99 | 2021 | |
| Aimmune Therapeutics, INC. | $60.49 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $47.57 | 2019-2023 | Linzess |
| Medtronic USA, INC. | $45.35 | 2019 | |
| Shionogi INC | $41.55 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $35.36 | 2019-2025 | |
| Amgen INC. | $31.07 | 2022-2023 | Avsola, Amjevita |
| Biocon Biologics INC | $24.18 | 2025 | Yesintek |
| Celltrion USA INC. | $19.44 | 2024 | Zymfentra |
| Organon LLC | $14.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Pitts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.